Balanced news tone
News Sentiment
KRYS sentiment intelligence
Krystal Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
59
Balanced news tone
56 relevant articles
Price is moving more forcefully than the current news tone suggests.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+9.5% over one week, +16.2% over four weeks, trend active, and materially above fair value.
Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
76/100 classification
One-week reaction
9.5%
Price confirming higher
Trend fit
Trend active
16.2% over four weeks
Fair value
96.0%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
25
Neutral
26
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Direct company coverage
A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Driven Earnings Beat And Pipeline Progress
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 04 Jun 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jun 2026 07:00
- Source
- Market source
Investing.com Canada
Direct company coverage
Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 18 May 2026 07:00
- Source
- Investing.com Canada
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
ChartMill
Direct company coverage
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 May 2026 07:00
- Source
- ChartMill
simplywall.st
Direct company coverage
Is It Too Late To Consider Krystal Biotech (KRYS) After Its Strong Share Price Run?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
Krystal Biotech CEO to speak May 13 at BofA health care event
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 05 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Krystal Biotech reports $116.4M in sales as key eye study fills
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Stock Titan
Market source
Direct company coverage
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Vyjuvek Label Update And KB803 Progress Reshape Krystal Biotech Story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Mar 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Is It Too Late To Consider Krystal Biotech (KRYS) After Strong Multi‑Year Share Gains?
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- Market source
Barron's
Direct company coverage
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Barron's
Market source
Direct company coverage
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 21 Feb 2026 08:00
- Source
- Market source
Finviz
Direct company coverage
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Feb 2026 08:00
- Source
- Finviz
Market source
Direct company coverage
Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 03 Feb 2026 08:00
- Source
- Market source
simplywall.st
Industry context
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Dec 2025 08:00
- Source
- simplywall.st
simplywall.st
Direct company coverage
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Oct 2025 07:00
- Source
- simplywall.st